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OBJECTIVE—The goal of this study was to characterize glyca-
tion adducts formed in both in vivo extracellular matrix (ECM)
proteins of endoneurium from streptozotocin (STZ)-induced
diabetic rats and in vitro by glycation of laminin and ﬁbronectin
with methylglyoxal and glucose. We also investigated the impact
of advanced glycation end product (AGE) residue content of
ECM on neurite outgrowth from sensory neurons.
RESEARCH DESIGN AND METHODS—Glycation, oxidation,
and nitration adducts of ECM proteins extracted from the
endoneurium of control and STZ-induced diabetic rat sciatic
nerve (3–24 weeks post-STZ) and of laminin and ﬁbronectin that
had been glycated using glucose or methylglyoxal were exam-
ined by liquid chromatography with tandem mass spectrometry.
Methylglyoxal-glycated or unmodiﬁed ECM proteins were used
as substrata for dissociated rat sensory neurons as in vitro
models of regeneration.
RESULTS—STZ-induced diabetes produced a signiﬁcant in-
crease in early glycation Nε -fructosyl-lysine and AGE residue
contents of endoneurial ECM. Glycation of laminin and ﬁbronec-
tin by methylglyoxal and glucose increased glycation adduct
residue contents with methylglyoxal-derived hydroimidazolone
and Nε -fructosyl-lysine, respectively, of greatest quantitative im-
portance. Glycation of laminin caused a signiﬁcant decrease in
both neurotrophin-stimulated and preconditioned sensory neu-
rite outgrowth. This decrease was prevented by aminoguanidine.
Glycation of ﬁbronectin also decreased preconditioned neurite
outgrowth, which was prevented by aminoguanidine and nerve
growth factor.
CONCLUSIONS—Early glycation and AGE residue content of
endoneurial ECM proteins increase markedly in STZ-induced
diabetes. Glycation of laminin and ﬁbronectin causes a reduction
in neurotrophin-stimulated neurite outgrowth and precondi-
tioned neurite outgrowth. This may provide a mechanism for the
failure of collateral sprouting and axonal regeneration in diabetic
neuropathy. Diabetes 58:2893–2903, 2009
T
he extracellular matrix (ECM) provides physical
support for cells and tissue and also has a crucial
role in regulating cell behavior and mediating
survival, proliferation, differentiation, and migra-
tion via interaction with speciﬁc cell adhesion receptors
such as integrins (1). Sensory neurons contain at least ﬁve
laminin-binding integrins and two ﬁbronectin-binding inte-
grins (2–5), and we and others (3,6) have shown the
1-integrins to be crucial mediators of neuronal adhesion
and nerve regeneration. Therefore, modiﬁcation of ECM
proteins by glycation in diabetes may have a severe impact
on cellular function.
Glycation of proteins involves the covalent linkage of
saccharides and saccharide derivatives to proteins. Glu-
cose reacts with amino groups of lysine and NH2-
terminal amino acid residues. Early stage reactions lead
to the formation of fructosyl-lysine and related fruc-
tosamine residues, which degrade slowly to form ad-
vanced glycation end products (AGEs). In addition to
degradation of glycated proteins, glycolytic intermedi-
ates and lipid peroxidation lead to the formation of the
reactive dicarbonyl metabolites, glyoxal, methylglyoxal,
and 3-deoxyglucosone (3-DG). Dicarbonyls form AGE
residues in proteins largely, but not exclusively, on
arginine residues. At the quantitative level, the most
abundant AGEs are the hydroimidazolones derived from
glyoxal, methylglyoxal, and 3-DG (denoted by the acro-
nyms G-H1, MG-H1, and 3DG-H), the lysine-derived
AGEs (Nε -carboxymethyl-lysine [CML] and Nε -carboxy-
ethyllysine [CEL]), imidazolium cross-links derived
from glyoxal, methylglyoxal, and 3-DG (GOLD, MOLD,
and DOLD), and the trace ﬂuorescent cross-link
pentosidine.
AGE residues accumulate in both intracellular and
extracellular proteins, especially in those with poorly
controlled diabetes and tissues with metabolic dysfunc-
tion associated with high cellular glucose concentration.
Accumulation of AGE residues is a risk marker for the
development of diabetic neuropathy (7–9). AGE formation
can be decreased by scavenging dicarbonyl precursors
with aminoguanidine (10), which suppresses neurovascu-
lar dysfunction in streptozotocin (STZ)-induced diabetic
rats (11,12).
ECM proteins are particularly long-lived, and they are
potential targets of glycation. Changes in the composi-
tion and structure of ECM of peripheral nerve are
observed in those with diabetes; notably increased
endoneurial collagen, reduplication of basement mem-
branes around endoneurial capillaries, and a thickening
of basal lamina are present in both clinical and experi-
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modiﬁes functionally important arginine residues of
RGD (arg-gly-asp) and GFOGER (gly-phe-hyp-gly-glu-
arg) motifs causing loss of charge and structural distor-
tion, which is associated with decreased binding afﬁnity
of integrins and cell detachment. It also produces
intramolecular cross-linking, causing structural distor-
tion, and may confer resistance to proteolysis, leading
to thickening of the basement membrane (17).
We have previously shown that cytosolic protein ex-
tracts of peripheral nerve of STZ-induced diabetic rats
have increased fructosyl-lysine and AGE residue content
compared with controls (7). In this current study, we ﬁrst
characterized and quantiﬁed AGE residue content in ECM
protein extracts from the endoneurium of STZ-induced
diabetic rat sciatic nerve over a 24-week time point.
Second, we glycated the ECM proteins, laminin and ﬁ-
bronectin, in vitro using glucose and methylglyoxal and
characterized and quantiﬁed the AGE residue contents of
these glycated and unmodiﬁed control proteins. To ad-
dress the functional impact of increased AGE residue
content in ECM proteins on axonal outgrowth, we used
two in vitro models of sensory nerve regeneration to
model both collateral sprouting and axonal regeneration
processes.
RESEARCH DESIGN AND METHODS
Reagents. All chemicals were obtained from Sigma-Aldrich (Poole, Dorset,
U.K.) unless otherwise stated. High-purity methylglyoxal was prepared by acid
hydrolysis of freshly distilled methylglyoxal dimethylacetal and puriﬁed by
fractional distillation under reduced pressure (18).
All studies and procedures were licensed under the U.K. Animals (Scientiﬁc
Procedures) Act 1986. Diabetes was induced in adult female Wistar rats (200–250
g, Charles River, U.K.) via intraperitoneal injection of freshly dissolved STZ (55
mg/kg in sterile saline) as previously described (19). Rats were killed at various
time points after induction of diabetes (3, 6, 9, 12, and 24 weeks post-STZ, n  6
at each time point), and the sciatic nerves were rapidly removed and frozen on
liquid nitrogen. Age- and weight-matched rats were used as nondiabetic controls
(time 0 and 24 weeks, n  4 at each time point).
A separate group of adult male Wistar rats (250–300 g, n  12) were
anesthetized with isoﬂuorane (2% in oxygen) under sterile conditions, and the
left sciatic nerve was exposed at mid-thigh level. The sciatic nerve was
crushed with the tips of watchmakers forceps (2  15 s), the wound was
closed, and animals recovered under observation. Seven days after nerve
crush, rats were killed by concussion followed by decapitation. Ipsilateral
and contralateral L4 and L5 dorsal root ganglia (DRG) were removed for cell
culture experiments.
ECM protein extraction from sciatic endoneurium. Sciatic nerves were
desheathed, homogenized in 0.25 mol/l sucrose on ice, and centrifuged at 900
g at 4°C. The ECM protein in the pellet was washed with PBS, then extracted
with chloroform:methanol (2:1, v:v) and stirred continuously for 24 h at 4°C
and centrifuged at 900 g at 4°C. The pellet was washed twice with PBS and
frozen at 80°C until analysis.
Glycation of ECM proteins. Laminin and ﬁbronectin modiﬁed by fructosyl-
lysine and AGEs (AGE-laminin and AGE-ﬁbronectin, respectively) were
prepared by incubating the proteins (6.6 mg/ml) with 50 mmol/l glucose in 100
mmol/l sodium phosphate buffer, pH 7.4, at 37°C for 21 days. Laminin and
ﬁbronectin were also modiﬁed by incubating the proteins (6.6 mg/ml) with 500
mol/l methylglyoxal in 100 mmol/l sodium phosphate buffer, pH 7.4, at 37°C
for 24 h. After the incubation, glycated and control proteins were dialyzed
against 30 mmol/l ammonium formate, pH 7.8 and 4°C; lyophilized to dryness;
and stored at 20°C.
Protein glycation, oxidation, and nitration adduct determination by
liquid chromatography–mass spectrometry/mass spectrometry. Protein
glycation, oxidation, and nitration adducts were determined by stable isotopic
dilution analysis liquid chromatography with tandem mass spectrophotometer
detection (7). Glycation adducts determined were fructosyl-lysine and 10
AGEs (CML, CEL, G-H1, MG-H1, 3DG-H, GOLD, MOLD, DOLD, argpyrimidine,
and pentosidine). The protein oxidation adduct dityrosine, the protein nitra-
tion adduct neurotrophin-3 (3-NT), and amino acids lys, arg, met, tyr, and trp
were also determined. Pentosidine was determined by liquid chromatography
with ﬂuorimetric detection (20). Authentic standard analyses were prepared
as described (7,21). Glycation, oxidation, and nitration adduct residues of
protein extracts were determined in exhaustive enzymatic digests (50 g
protein equivalent) (22). Samples were analyzed using a module 2690 separa-
tion module with a Quattro Ultima triple-quadrupole mass spectrometric
detector and 2475 ﬂuorescence detector (Waters-Micromass, Manchester,
U.K.) as previously described (20).
Sensory neuron culture. Control or preconditioned (7 days postunilateral
sciatic nerve crush injury) adult rat sensory neurons were mechanically and
chemically dissociated, puriﬁed, and resuspended in modiﬁed Bottenstein and
Sato’s medium in Ham’s F12 (containing 10 mmol/l D-glucose) as previously
described (6,19,23).
Coating of slides with ECM. Labtek slides (VWR, U.K.) were either coated
directly with 2 g/ml laminin or derivatized for 30 min with 1 mmol/l
m-maleimidobenzoyl-N-hydroxysuccinimide ester (Pierce Chemical, Rock-
ford, IL) before coating for1ha troom temperature with 10 g/ml ﬁbronectin
(24). Methylglyoxal (500 mol/l), aminoguanidine (500 mol/l), methylglyoxal
with aminoguanidine (both 500 mol/l), or PBS was added to appropriate
wells and slides incubated for 24 h at 37°C. Slides were washed three times
and neurons were seeded onto slides in Bottenstein and Sato’s medium and
allowed to adhere to the substrate for 1 h before addition of nerve growth factor
(NGF) (10 ng/ml) or glial cell-derived neurotrophic factor (GDNF) (50 ng/ml,
Promega). Neurons were incubated for 18 h in 5% CO2 at 37°C and immuno-
stained with anti–(III)-tubulin antibody (1:1,000, Sigma), a pan-neuronal marker
labeling all cell bodies and neurites as previously described (23).
Neurite outgrowth analysis. For each experimental condition, images of
neurons were acquired from 20 randomly selected ﬁelds of view per
condition. Assessors were blinded to the experimental condition during
analysis. The mean number of neurite-bearing cells was calculated (deﬁned
as those with neurites longer than 1.5 times the associated cell body
diameter). The length of the longest neurite from each cell was calculated
using SigmaScan software (SPSS, U.K.), as was a measure of total neurite
outgrowth: a series of concentric circles was overlaid onto an image of
each neuron, and the number of times neurites crossed each circle was
calculated. This provided both a measure of total neurite outgrowth (total
number of cross points) and neurite branching structure (cross points
related to distance from the cell body). All these measurements were made
from cells in the 20 randomly selected ﬁelds in each experiment and
repeated in at least four independent cultures (23). Data are expressed as
means  SD. Statistical analysis was conducted using Graphpad Prizm
software using ANOVA followed by Bonferroni post hoc test.
RESULTS
Glycation, oxidation, and nitration adduct residue
content of endoneurial ECM proteins in experimen-
tal diabetes. To determine whether diabetes altered the
extent of adduct residue content on endoneurial ECM
proteins, we assessed 14 markers of glycation, oxidation,
and nitration by liquid chromatography–mass spectrome-
try/mass spectrometry. Ten of the 14 markers investigated
were present in detectable amounts in endoneurial ECM
proteins from control and STZ-induced diabetic rats.
These were fructosyl-lysine, CML, CEL, G-H1, MG-H1,
3DG-H, MOLD, pentosidine, MetSO, and dityrosine. The
protein damage marker residues below the limit of detec-
tion (LOD) were GOLD, DOLD, argpyrimidine, and 3-NT.
Estimates of pentosidine residues were LOD in 33% of
cases (STZ-induced diabetic study groups) and were set to
the LOD in such cases for statistical analysis. For indexes
of diabetes refer to Table 1.
After induction of diabetes, there were signiﬁcant in-
creases in the amount of fructosyl-lysine, CML, G-H1, and
MG-H1 adduct residue contents on endoneurial ECM
proteins (Fig. 1A–D). There were no signiﬁcant changes in
CEL (0.083  0.025 mmol/mol lys), pentosidine (0.0016 
0.0009 mmol/mol lys), MOLD (0.004  0.003 mmol/mol
lys), MetSO (31.3  8.7 mmol/mol met), and dityrosine
(0.29  0.13 mmol/mol tyr) residue contents and a onefold
increase of 3DG-H residues (1.26  0.69 vs. 0.67  0.13
mmol/mol arg; P  0.05) after 6 weeks of diabetes. For
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diabetes after reaching a maximum content at 6 weeks of
diabetes and rebound to higher contents after 24 weeks.
There were no age-related changes in adduct residue
contents over the 24-week time course studied (Fig. 1A–D;
no signiﬁcant differences in AGE content between endo-
neurial ECM protein samples at time 0 or 24 weeks
post-STZ; P  0.05). These results indicate that the in-
crease in fructosyl-lysine, CML, G-H1, and MG-H1 residue
contents of ECM proteins of the sciatic nerve endo-
neurium correlates with the development of STZ-induced
diabetes.
Glycation of ECM proteins by methylglyoxal and
glucose in vitro. To test the hypothesis that ECM pro-
teins are susceptible to glycation under physiological
conditions, we incubated laminin and ﬁbronectin with
methylglyoxal or glucose. Note that similar conditions
used with human serum albumin (HSA) produced HSA
modiﬁed minimally with glycation adducts (1–2 molar
equivalents) (25). Control ﬁbronectin and laminin had
minor but signiﬁcant contents of glycation adducts
fructosyl-lysine, CML, MG-H1, and 3DG-H, ranging from
0.2–2.3 mol/mol protein and some protein oxidation (1–6
equivalents of MetSO residues) but no detectable dity-
rosine or 3-NT (Tables 2 and 3).
Glycation of ﬁbronectin by methylglyoxal produced 	28
equivalents of MG-H1. This was the major methylglyoxal-
derived AGE formed (97%), the others being CEL (0.06
mol; 0.2%), argpyrimidine (0.79 mol; 3%), and MOLD (0.002
mol; 0.01%); the total methylglyoxal-derived adduct in-
crease was 	29.2 molar equivalents, representing 88%
of the added methylglyoxal (Table 2). Similarly, glycation
of laminin by methylglyoxal produced 	56 equivalents of
MG-H1 (88%), together with CEL (0.53 mol: 0.8%), argpyri-
TABLE 1
Indexes of STZ-induced diabetes over 24-week time period
Experimental
group (n)
Body wt (g) Terminal blood
glucose levels
(mmol/l)
Motor nerve conduction
velocity (m/s)
Sensory nerve
conduction
velocity (m/s) Start End
Control 0 231  10 231  10 n.t. n.t. n.t.
Control 24 weeks 239  5 361  53 n.t. 58.7  9.2 57  4.8
STZ 3 weeks 233  7 215  21 26  3.7 n.t. n.t.
STZ 6 weeks 242  10 257  15 26.9  1.4 n.t. n.t.
STZ 9 weeks 242  17 271  27 25.4  2.9 n.t. n.t.
STZ 12 weeks 233  13 264  41 21.5  7.6 n.t. n.t.
STZ 24 weeks 233  16 319  55 23.3  7.9 43.2  5.4* 45.5  3.9*
Data are means  SD unless otherwise indicated. *P  0.005: t test, control vs. diabetic nerve conduction velocity at 24 weeks. n.t.  not
tested.
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FIG. 1. Glycation adduct content of endoneurial ECM proteins of STZ-induced diabetic rat sciatic nerve. N-fructosyl-lysine (A), CML (B), G-H1
(C), and MG-H1 (D). Data are given for nondiabetic control (con) rats at 0 and 24 weeks of the experiment and for STZ-induced diabetic rats with
duration of diabetes 3–24 weeks (post–STZ injection). Data are means  SE (n  6–8 for STZ-induced diabetic groups; n  4 for nondiabetic
controls). Signiﬁcance: *P < 0.05, **P < 0.01 compared with nondiabetic controls (Kruskal-Wallis). FL, fructosyl-lysine.
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total adduct methylglyoxal-derived adduct increase was
	63.1 molar equivalents, representing 93% of the added
methylglyoxal (Table 3).
Glycation of ﬁbronectin by glucose gave a relatively
modest increase in glycation adduct residues: fructosyl-
lysine (0.52 mol; 61% detected adduct residue increase),
3DG-H (0.32 mol; 36%), and trace amounts of MG-H1 and
pentosidine (Table 2). Glycation of laminin by glucose
gave much higher increases of glycation adduct residues:
fructosyl-lysine (21 mol; 81%), 3DG-H (3.7 mol; 14%), CML
(1.1 mol; 4%), G-H1 (0.2 mol; 0.8%), and trace amounts of
CEL, MOLD, and pentosidine. As expected, pentosidine
residue content was very low in all proteins analyzed,
0.01 mol% (Table 3).
Sensory nerve regeneration is impaired on glycated
ECM. Because experiments using function-blocking anti-
bodies have highlighted the essential role that laminin and
ﬁbronectin play in promoting axonal outgrowth, we hy-
pothesized that glycation of these proteins may contribute
directly to failure of axonal regeneration (26,27).
To test this hypothesis, we examined the ability of disso-
ciated adult rat sensory neurons to form neurites in culture.
The addition of neurotrophic factors during the ﬁrst 18 h
promotes neurite outgrowth in deﬁned populations of sen-
sory neurons, which enabled us to compare regeneration of
different populations of neurons on glycated versus unmod-
iﬁed laminin and ﬁbronectin. Sensory neurons in culture
exhibit two distinct forms of neurite outgrowth: an initial,
short arborizing form of neurite outgrowth, which occurs in
the absence of neurotrophic factors (but is enhanced by
addition of NGF, NT-3, or GDNF), followed by a transcrip-
tion-dependent switch to axon elongation. The arborizing
growth is analogous to the collateral sprouting of terminal
ﬁelds seen in vivo, whereas elongation is analogous to axon
regeneration in vivo (28).
Survival of sensory neurons was not altered on
methylglyoxal-glycated laminin in comparison to untreated
laminin (assessed using trypan blue 18 h after plating, data
not shown), nor was the percentage of neurite-bearing cells
(Fig. 2D).
Neurons plated on laminin extended highly arborised
neurites in the presence of NGF (Fig. 2A). In contrast, neurite
outgrowth was dramatically lower on methylglyoxal-glycated
laminin (Fig. 2B). Quantiﬁcation of NGF-stimulated neurite
outgrowth showed no signiﬁcant decrease in the length of
longest neurite (Fig. 2E) but signiﬁcant reduction in total
neurite density and branching, as measured by cross-point
analysis (total neurite density: laminin 160  28 cross points
vs. methylglyoxal-glycated laminin 90  18 cross points, P 
0.05; at 100 m from cell body: laminin 32 3 cross points vs.
methylglyoxal-glycated laminin 17.4  3 cross points, P 
TABLE 2
Glycation adduct residue contents of human ﬁbronectin glycated by methylglyoxal and glucose (AGE)
Glycation
adduct
Methylglyoxal-
ﬁbronectin
control-1*
Methylglyoxal-
ﬁbronectin
AGE-ﬁbronectin
control-2† AGE-ﬁbronectin
Fructosyl-lysine 0.213  0.034 0.215  0.088 0.094  0.022 0.610  0.088¶
CML 0.119  0.025 0.202  0.041‡ 0.079  0.021 0.092  0.020
CEL 0.008  0.001 0.067  0.016‡ 0.007  0.001 0.014  0.005
G-H1 0.016  0.004 0.046  0.007§ 0.005  0.002 0.008  0.001
MG-H1 0.239  0.013 28.42  0.97¶ 0.176  0.006 0.198  0.006‡
3DG-H 0.217  0.068 0.819  0.215 0.420  0.066 0.727  0.044§
Argpyrimidine LOD 0.793  0.060¶ LOD LOD
MOLD 0.0021  0.0001 0.0039  0.0003¶ 0.0015  0.0001 0.0030  0.0008
Pentosidine 0.000015  0.000001 0.000129  0.000010¶ 0.000007  0.000001 0.000012  0.000001¶
MetSO 1.05  0.09 3.15  0.16¶ 0.40  0.04 0.38  0.02
Data are mol/mol ﬁbronectin; means  SD (n  3). *Fibronectin incubated under the conditions to control for glycation by methylglyoxal.
†Fibronectin incubated under the conditions to control for glycation by glucose. LOD indicates argpyrimidine residue content is less than
the limit of detection (0.001 mol/mol ﬁbronectin). Other adducts not detected were (mol/mol): GOLD and dityrosine 0.0006, DOLD
0.0002, and 3-NT 0.0001. ‡P  0.05, §P  0.01, ¶P  0.001; t test.
TABLE 3
Glycation adduct contents of laminin minimally modiﬁed by methylglyoxal and glucose (AGE)
Glycation
adduct
Methylglyoxal-
laminin control-1*
Methylglyoxal-
laminin
AGE-laminin
control-2† AGE-laminin
FL 0.777  0.100 0.698  0.047 1.11  0.35 21.84  0.58¶
CML 0.303  0.052 0.332  0.070 0.353  0.027 1.420  0.094¶
CEL 0.035  0.009 0.562  0.047¶ 0.029  0.004 0.055  0.010‡
G-H1 0.022  0.009 0.021  0.011 0.031  0.001 0.229  0.060§
MG-H1 0.87  0.04 56.57  1.78¶ 1.44  0.10 1.66  0.16
3DG-H 2.31  0.29 1.34  0.36‡ 2.26  0.16 5.97  0.57§
Argpyrimidine LOD 6.82  0.56 LOD LOD
MOLD 0.0030  0.0011 0.0448  0.0081‡ 0.0018  0.0006 0.0074  0.0012§
Pentosidine 0.000036  0.000002 0.000045  0.000001‡ 0.000052  0.000002 0.000089  0.000004¶
MetSO 6.01  0.23 5.91  1.56 4.81  0.88 3.89  1.32
Data are mol/mol laminin; means  SD (n  3). LOD indicates argpyrimidine residue content is less than the limit of detection (0.002
mol/mol laminin). Other adducts not detected were (mol/mol): GOLD and dityrosine 0.0012, DOLD 0.0004, and 3-NT 0.0002. *Laminin
incubated under the conditions to control for glycation by methylglyoxal. †Laminin incubated under the conditions to control for glycation
by glucose. ‡P  0.05, §P  0.01, ¶P  0.001; t test.
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neurites in response to NGF on glycated laminin had fewer
and less-branched neurites than those plated on control
unmodiﬁed laminin. To conﬁrm this decrease was associated
with glycation, methylglyoxal-glycation was conducted in the
presence of the glycation scavenger aminoguanidine, which
prevented the deﬁcits in neurite outgrowth (Fig. 2C, F, and
G).
The GDNF-responsive subpopulation of neurons was
similarly disadvantaged when plated on glycated laminin
(Fig. 3). There were signiﬁcant glycation-associated de-
creases in the length of longest neurite (Fig. 3B and E),
total neurite outgrowth (total neurite density: 64.7  28.6
cross points on laminin vs. 21.2  18.2 cross points on
methylglyoxal-glycated laminin, P  0.05; Fig. 3B and F)
and a reduction in branching structure (Fig. 3B and G).
These deﬁcits were also prevented by inclusion of
aminoguanidine.
Diabetes is associated with the initial presence of
regenerative axon proﬁles alongside degenerative struc-
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FIG. 2. Sensory neurons plated on glycated laminin and treated with NGF extend fewer, less-branched neurites than those plated on control unmodiﬁed
laminin. Representative photomicrographs of sensory neurons plated on laminin (A), laminin glycated with methylglyoxal (B), or laminin treated with
methylglyoxal in the presence of aminoguanidine (C). NGF treatment (10 ng/ml; 18 h) stimulated neurons plated on laminin to extend elaborate highly
branched neurites (A). In contrast, NGF-stimulated neurite outgrowth on methylglyoxal-glycated laminin was much less extensive (B); this was prevented
by inclusion of aminoguanidine (C). Quantiﬁcation of NGF-stimulated neurite outgrowth showed no signiﬁcant reduction in length of longest neurite (E) but
a signiﬁcant reduction in total neurite density and branching structure, compared with control, as measured by cross-point analysis (F and G), which was
prevented by inclusion of the glycation scavenger aminoguanidine (C,F, and G). Data are expressed as means SD; n4 independent cultures (ANOVA and
Bonferroni multiple-comparison post hoc test, *P < 0.05). Aminoguanidine treatment alone had no signiﬁcant effect on any of the indexes examined (D–G;
P > 0.05). Scale bar  100 m. AG, aminoguanidine; LM, laminin; MG, methylglyoxal.
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tive phenotype, we used a preconditioning nerve-crush
injury model that can potentiate the capacity of sensory
neurons to mount a regenerative response after a sub-
sequent injury to their axons (30,31). Control sensory
neurons extend neurites very poorly on ﬁbronectin
compared with growth on laminin; however, neurite
outgrowth is enhanced by a preconditioning crush to the
sciatic nerve in vivo 7 days before culture (23). There-
fore, we used this model to investigate the impact of
glycation of laminin and ﬁbronectin on sensory nerve
regeneration.
Preconditioned neurons plated on laminin extended
some neurites even in the absence of exogenous neurotro-
phins (Fig. 4A), but growth was strongly enhanced by
addition of NGF (Fig. 4D) or GDNF (Fig. 4G). Glycation of
laminin signiﬁcantly reduced preconditioned neurite out-
growth in all treatment conditions (Fig. 4B, E, and H). This
reduction was prevented by inclusion of aminoguanidine
(Fig. 4C, F, and I). Quantiﬁcation of preconditioned neu-
rite outgrowth showed signiﬁcant glycation-associated de-
creases in the length of longest neurite and total neurite
density (Fig. 4J and K).
Preconditioned neurite outgrowth was also observed on
ﬁbronectin in the absence of neurotrophic support (Fig. 5A),
which was strongly enhanced by GDNF but not NGF (in
agreement with our previous study [23]). In neurons plated
on glycated ﬁbronectin, neurite outgrowth was signiﬁcantly
impaired, both in the absence of neurotrophins and in the
presence of GDNF (Fig. 5B, D, J, and K). As before, inclusion
of aminoguanidine prevented the glycation-mediated inhibi-
tion. Interestingly, the addition of NGF to preconditioned
0
20
40
60
80
100
0
50
100
150
200
250
300
0
4
8
12
16
20
0
4
8
12
16
LM
LM + MG
L M+M G+A G
LM + AG
AB
LM LM LM + +M G M G+  A G
C
s
t
n
i
o
p
s
s
o
r
c
l
a
t
o
T
s
l
l
e
c
g
n
i
r
a
e
b
-
e
t
i
r
u
e
n
%
(
e
t
i
r
u
e
n
t
s
e
g
n
o
l
f
o
h
t
g
n
e
L
                                          m
 
)
s
t
n
i
o
p
s
s
o
r
C
D E
F G
LM LM + LM + LM +
MG MG +
AG
AG
LM LM +
MG
LM +
MG +
AG
LM +
AG
*
LM LM +
MG
LM +
MG +
AG
LM +
AG
*
Distance from cell body ( m)
66 100 133 166 200 233 266 300 333 366
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rite outgrowth (Fig. 5J and K).
These results show that ECM glycation has a dramatic
inhibitory effect on the ability of sensory neurons to
extend neurites in response to neurotrophic factors as
well as to regenerate after a preconditioning injury.
DISCUSSION
The accumulation of proteins damaged by formation of
AGE residues in the peripheral nerve in diabetes has been
linked to changes in nerve structure and neuronal function
and development of diabetic neuropathy (32). We have
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FIG. 4. Enhanced neurite outgrowth in response to a preconditioning sciatic nerve crush is reduced in neurons plated on glycated laminin.
Representative photomicrographs of neurons from L4 and L5 DRG ipsilateral to a crush injury to the sciatic nerve (7 days before culture), which were
dissociated and plated on laminin (A, D, and G), laminin glycated with methylglyoxal (B, E, and H), or laminin treated with methylglyoxal in the
presence of aminoguanidine (C, F, and I) for 18 h with (D–I) or without (A–C) neurotrophin treatment (D–F, 50 ng/ml GDNF; G–I, 10 ng/ml NGF). The
preconditioned neurons extend neurites in the absence of neurotrophic support (A–C); this was enhanced by neurotrophin treatment (D–I). Two
parameters of neurite extension were quantiﬁed: total neurite outgrowth (J, cross points) and length of longest neurite (K). Neurons plated on
glycated laminin showed a signiﬁcant reduction in length of longest neurite and total neurite density compared with control, which was prevented by
inclusion of the glycation scavenger aminoguanidine (C, F, and I–K). All data are expressed as means  SD, n  4 independent experiments (ANOVA
with Bonferroni post hoc test, *P < 0.05, **P < 0.01). Scale bar  100 m. AG, aminoguanidine; LM, laminin; MG, methylglyoxal.
B. DURAN-JIMENEZ AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 58, DECEMBER 2009 2899now conducted experiments that suggest that the glyca-
tion of two central ECM proteins associated with neuronal
regeneration, laminin and ﬁbronectin, may be linked di-
rectly to the failure of axonal regeneration in diabetic
neuropathy. We have previously shown that cytosolic
protein extracts of peripheral nerve of STZ-induced dia-
betic rats have increased fructosyl-lysine and AGE residue
content (7). Here, we extend those ﬁndings by demonstrat-
ing that ECM proteins are also glycated in the endo-
neurium of rat sciatic nerves. Moreover, glycation of ECM
proteins with methylglyoxal increases AGE formation and
decreases the ability of adult rat sensory neurons to
extend neurites.
Endoneurial ECM proteins are glycated in vivo. The
epidermis is innervated by the free axon terminals of small-
diameter unmyelinated peptidergic and nonpeptidergic sen-
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methylglyoxal in the presence of aminoguanidine (C, F, and I) for 18 h with (D–I) or without (A–C) neurotrophin treatment (D–F, 50 ng/ml GDNF;
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their responsiveness to speciﬁc neurotrophins. The peptider-
gic population expresses trkA and responds to NGF, whereas
the nonpeptidergic population expresses receptors for
GDNF: ret and GFR (34,35). Because it is the peripheral
processes of these small-diameter neurons that degenerate in
clinical (36) and experimental diabetic neuropathy (37–39),
we focused our attention on the response of these popula-
tions of small-diameter neurons to ECM glycation.
Experimental diabetes in rats led to a profound increase
in early glycation adduct and AGE residues in endoneurial
ECM proteins of the sciatic nerve. The most abundant
AGE residue was MG-H1, which increased 	 ﬁvefold after
6 weeks of diabetes. Similarly, fructosyl-lysine residue
content increased from sixfold after 3 weeks of diabetes to
13-fold after 12 weeks. This is a higher increase than that
seen for plasma glucose concentration but nevertheless is
in keeping with the high (14-fold) increase of glucose
concentration reported in sciatic nerve in STZ-induced
diabetic rats (40). The ﬁvefold increased content of MG-H1
residues is higher than the twofold increase in plasma
concentration of methylglyoxal in STZ-induced diabetic
rats and may reﬂect downregulation of glyoxalase 1, which
provides the major defense against methylglyoxal glyca-
tion in diabetes (41,42). The accumulation of MG-H1
residues may be particularly damaging as it targets func-
tional domains of ECM proteins, particularly arginine
residues of RGD and GFOGER motifs, which are the major
integrin-binding motifs (43,44).
Glycation of laminin and ﬁbronectin in vitro. Further
evidence for the reactivity of ECM proteins toward glyca-
tion was obtained by glycation of ﬁbronectin and laminin
in vitro. We used conditions for glycation by methylglyoxal
where similar preparation of HSA produced a low or
minimal extent of modiﬁcation (2.49 equivalents of MG-H1
per mol [45]). Fibronectin and laminin were modiﬁed by
methylglyoxal to produce 28 and 56 MG-H1 residues per
mol protein, respectively. The arginine residue equivalents
in these incubations of HSA, ﬁbronectin, and laminin were
2.40 mmol/l, 1.86 mmol/l, and 2.50 mmol/l, and the concen-
trations of MG-H1 residues formed in methylglyoxal-
modiﬁed HSA, ﬁbronectin, and laminin were 2.5 mmol/l,
4.2 mmol/l, and 4.1 mmol/l, respectively. Assuming pseudo
ﬁrst-order reaction kinetics for the reaction of methylg-
lyoxal with arginine residues in these proteins, ﬁtting of
these data to a ﬁrst-order integrated rate equation indi-
cates under the conditions studied the mean reactivity of
arginine residues in ﬁbronectin and laminin is circa three-
to fourfold higher than in HSA. As the RGD residues are
preferentially modiﬁed, it is likely that the reactivities of
arginine residues in RGD motifs of laminin and ﬁbronectin
are much higher than this. These deductions provide
support for proposing ECM proteins as targets for hot spot
dicarbonyl glycation in diabetes.
Similar considerations for the formation of fructosyl-
lysine residues in the glycation of HSA (22) ﬁbronectin and
laminin by glucose show that the ﬁnal increased concen-
trations of fructosyl-lysine residues in the incubation were
114 mol/l, 8 mol/l, and 152 mol/l. As neither lysine
residues nor glucose were markedly depleted in these
reactions, an appropriate kinetic comparison may be made
by considering these data as a measure of initial rates of
glycation. The lysine residue concentrations in the incu-
bations of 6.6 mg/ml HSA, ﬁbronectin, and laminin are
circa 5.9 mmol/l, 1.2 mmol/l, and 2.3 mmol/l, respectively.
The reactivity of lysine residues toward formation of
fructosyl-lysine residues in HSA, ﬁbronectin, and laminin
is in the ratio 1:0.35:3.5 (not accounting for fructosyl-lysine
residue degradation). Glycation of ECM proteins by meth-
ylglyoxal in vivo is likely to originate from methylglyoxal
formed from cellular metabolism. High-dose thiamine
therapy decreased plasma methylglyoxal concentration
and glycation of aortal collagen by methylglyoxal by
correction of dysfunctional cell metabolism downstream
of glucose, without change in fructosyl-lysine residue
content (46). Together, our data show that laminin is
particularly susceptible to glycation by glucose.
ECM glycation dramatically impairs neuronal out-
growth and regeneration. Glycation of laminin with
glycoraldehyde (47) or glucose (48) has previously been
shown to reduce attachment and neuritogenesis in neona-
tal sensory neurons (47) and neurite extension from
mouse DRG explants (48). In this study, we use two
models of regeneration to demonstrate that methylglyoxal-
glycation of laminin and ﬁbronectin causes a reduction in
neurite outgrowth from speciﬁc populations of sensory
neurons after stimulation with neurotrophins and a reduc-
tion in preconditioned neurite outgrowth. Glycation of
ﬁbronectin with methylglyoxal impairs adhesion of
smooth muscle cells (49), retinal pericytes (50), and endo-
thelial progenitor cells (51). Similarly, methylglyoxal gly-
cation of the RGD domain of collagen IV inhibits 
v3
integrin binding and endothelial cell adhesion (43,44). We
previously implicated 
51 integrin binding to the RGD
domain of ﬁbronectin as being of key importance in the
neurite outgrowth of preconditioned neurons (23) and
suggest that glycation of the RGD domain is also respon-
sible for the impaired neurite outgrowth on glycated
ﬁbronectin. ECM integrin binding not only provides a
physical anchor point between the intracellular actin
cytoskeleton and the outside environment, enabling trac-
tion to mechanically drive axonal outgrowth, but also
directly regulates important intracellular signaling cas-
cades and subsequent gene transcription at the site of the
focal adhesion (52). Indeed, using Affymetrix gene mi-
croarray analysis we have identiﬁed over 500 genes whose
expression is signiﬁcantly altered in NGF-treated neurons
plated on methylglyoxal-glycated laminin compared with
unmodiﬁed laminin (data not shown). Replacement ther-
apy with exogenous NGF in diabetic rats normalizes key
molecular and functional aspects of neuropathy in vivo
(53,54). Although the mechanism of the observed NGF-
induced rescue of axonal regeneration on glycated ﬁ-
bronectin remains to be elucidated, our initial experiments
suggest it is not mediated via RAGE (receptor for AGEs)
because function-blocking experiments using anti-RAGE
did not affect neurite outgrowth on glycated ﬁbronectin.
Failure of axonal regeneration is a key feature of both
clinical and experimental diabetic neuropathy (55). In
uninjured peripheral nerve samples from patients with
diabetic neuropathy, clusters of regenerating axons can
initially be observed alongside degenerating axons; how-
ever, as the disease progresses there is a decline in the
number of regenerating axons (29). The regenerative re-
sponse of the peripheral nerve after injury is also blunted
in diabetes; little axonal regeneration is observed after
sural nerve biopsy (56) or epidermal nerve ﬁber injury
(57). We suggest that AGE accumulation in the endoneur-
ial ECM may contribute to this progressive failure of
axonal regeneration in diabetic neuropathy.
In conclusion, we have shown that ECM proteins are
glycated in the endoneurium of rat sciatic nerves in
B. DURAN-JIMENEZ AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 58, DECEMBER 2009 2901STZ-induced diabetes. Furthermore, glycation of laminin
and ﬁbronectin with methylglyoxal caused a reduction in
both neurotrophin-stimulated and preconditioned neurite
outgrowth from sensory neurons. This may provide a
potential mechanism for the failure of collateral sprouting
and axonal regeneration observed in diabetic neuropathy
and may represent an important, if challenging, target for
therapeutic intervention.
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